Risk factors, clinical features, and short-term prognosis of spontaneous fungal peritonitis in cirrhosis: A matched case-control study

Table 2 Comparison of clinical manifestations between spontaneous fungal peritonitis and fungiascites

Variable	Total (n = 35)	SFP (n = 22)	Fungiascites (n = 13)	P-value
Antibiotic treatment before peritonitis (d)	12 (5.0-23.0)	15.4 (3.8-24.8)	12.0 (6.0-22.0)	0.8
Anti-fungal therapy	15 (42.9%)	8 (36.4%)	7 (53.8%)	0.48
Septic shock n (%)	8 (22.9%)	7 (31.8%)	1 (4.2%)	0.21
WBC, 109 cells/L (IQR)	9.4 (5.6-18.1)	11.7 (8.2-19.1)	6.8 (3.6-12.0)	0.046
C-reactive protein, mg/L (IQR)	69.0 (33.3-110.5)	77.4 (55.9-138.2)	36.6 (13.4-72.1)	0.01
SIRS n (%)	19 (54.3%)	14 (63.6%)	5 (38.5%)	0.18
Fungus
Candida spp.	26 (74.2%)	18 (81.8%)	8 (61.5%)	-
Trichosporon	2 (5.7%)	1 (4.5%)	1 (7.6%)	-
Aspergillus	5 (14.3%)	3 (13.6%)	2 (15.3%)	-
Cryptococcus laurentii	2 (5.7%)	0 (0%)	2 (15.3%)	-
Severity score
SOFA (M ± SD)	6.8 ± 3.5	7.1 ± 3.8	5.2 ± 2.6	0.77
MELD (IQR)	14.7 (8.0-24.3)	15.9 (7.5-25.2)	14.2 (8.8-24.8)	0.92
CTP (IQR)	11.0 (9.0-12.0)	11.0 (8.0-12.3)	11.0 (9.0-11.5)	0.7
15-d mortality	13 (37.1%)	10 (45.1%)	3 (23.7%)	0.28

M: Mean; SD: Standard deviation; IQR: Interquartile range; SOFA: Sequential organ failure assessment; MELD: Model for end-stage liver disease; CTP: Child-Turcotte-Pugh.